Identification of N,N-dimethyltryptamine and β-carbolines in psychotropic ayahuasca beverage

Biomedical Chromatography

Volumn 22, Issue 10, 2008, Pages 1056-1059

  Gambelunghe, Cristiana ^a   Aroni, Kyriaki ^a   Rossi, Riccardo ^b   Moretti, Luca ^a   Bacci, Mauro ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Ayahuasca; Gas chromatography mass spectrometry; Harmaline; Harmine; N,N dimethyltryptamine; Psychotropic drugs

Indexed keywords

BEVERAGES; GAS CHROMATOGRAPHY; PLANTS (BOTANY); PYRIDINE;

AYAHUASCUM; GASCHROMATOGRAPHY-MASS SPECTROMETRY; HARMALINE; HARMINE; MASS SPECTROMETRY ANALYSIS; MONOAMINE OXIDASE A; N,N-DIMETHYLTRYPTAMINE; PROPERTY; PSYCHOTROPIC DRUGS; Β-CARBOLINE;

SPECTROMETRY;

BETA CARBOLINE DERIVATIVE; HARMALINE; HARMINE; N,N DIMETHYLTRYPTAMINE; PSYCHOTROPIC AGENT; CARBOLINE DERIVATIVE;

ARTICLE; AYAHUASCA; BEVERAGE; DRUG DETERMINATION; MASS FRAGMENTOGRAPHY; SOUTH AMERICA; BANISTERIOPSIS; CHEMISTRY; METHODOLOGY;

BANISTERIOPSIS CAAPI; PSYCHOTRIA VIRIDIS;

BANISTERIOPSIS; BEVERAGES; CARBOLINES; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; N,N-DIMETHYLTRYPTAMINE;

EID: 58149143196     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1023     Document Type: Article

References (13)

1. Carlini EA. Plants and the central nervous system. Pharmacology, Biochemistry and Behavior 2003; 75: 501-512.
2. Halpern JH. Hallucinogens and dissociative agents naturally growing in the United States. Pharmacology and Therapeutics 2004; 102: 131-138.
3. McKenna DJ. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacology and Therapeutics 2004; 102: 111-129.
4. McKenna DJ and Towers GH. Biochemistry and pharmacology of tryptamines and beta-carbolines. A minireview. Journal of Psychoactive Drugs 1984; 16: 347-358.
5. Riba J, Rodríguez A-Fornells, Urbano G, Morte A, Antonijoan R, Montero M, Callaway JC and Barbanoj MJ. Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology (Berlin) 2001; 154: 85-95.
6. Riba J, Valle M, Urbano G, Yritia M, Morte A and Barbanoj MJ. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. The Journal of Pharmacology and Experimental Therapeutics 2003; 306: 73-83.
7. Riba J, Romero S, Grasa E, Mena E, Carrió I and Barbanoj MJ. Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology (Berlin) 2006; 186: 93-98.
8. Sklerov J, Levine B, Moore KA, King T and Fowler D. A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an Ayahuasca preparation. Journal of Analytical Toxicology 2005; 29: 838-841.
9. Strassman RJ and Qualls CR. Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Archives of General Psychiatry 1994; 51: 85-97.
10. Strassman RJ, Qualls CR, Uhlenhuth EH and Kellner R. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Archives of General Psychiatry 1994; 51: 98-108.
11. Stuckey DE, Lawson P and Luna LE. EEG gamma coherence and other correlates of subjective reports during Ayahuasca experiences. Journal of Psychoactive Drugs 2005; 37: 163-178.
12. Winkelmann M. Drug tourism or spiritual healing? Ayahuasca seekers in Amazonia. Journal of Psychoactive Drugs 2005; 37: 209-218.
13. Yritia M, Riba J, Ortuño J, Ramirez A, Castillo A, Alfaro Y, de la Torre R and Barbanoj MJ. Determination of N,N-dimethyltripatamine and β-carboline alkaloids in human plasma following oral administration of Ayahuasca. Journal of Chromatography B 2002; 779: 271-281.